---
schema_version: "secwatch.filing_event.v1"
accession: "0001534120-26-000044"
form_type: "8-K"
ticker: "AVTX"
cik: "0001534120"
company_name: "Avalo Therapeutics, Inc."
filed_at: "2026-06-23T11:01:57+00:00"
generated_at: "2026-06-23T11:05:09.354953+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# Avalo Therapeutics appoints Ron Philip to Board of Directors

## Summary
- Ron Philip appointed to board effective June 23, 2026; will serve until 2027 annual meeting.
- Appointed to Compensation Committee and Science, Development and Commercial Advisory Committee.
- Received non-qualified stock option to purchase 40,200 shares, vesting over 3 years.
- Mr. Philip most recently was CEO of Orbital Therapeutics until its acquisition by Bristol-Myers Squibb in Dec 2025.
- Board determined Mr. Philip satisfies Nasdaq independence standards.

## SEC filing metadata
- accession: 0001534120-26-000044
- form_type: 8-K
- ticker: AVTX
- cik: 0001534120
- company_name: Avalo Therapeutics, Inc.
- filed_at: 2026-06-23T11:01:57+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1534120/000153412026000044/0001534120-26-000044-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1534120/000153412026000044/avtx-20260623.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001534120-26-000044
- JSON: https://secwatch.observer/filing/0001534120-26-000044.json
- Plain text: https://secwatch.observer/filing/0001534120-26-000044.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.